FDA approves new Covid shots with limits on who can get them, as RFK Jr. changes vaccine precedents

FDA approves new Covid shots with limits on who can get them, as RFK Jr. changes vaccine precedents


Pfizer’s Covid vaccine Comirnaty, seen at a CVS Pharmacy in Eagle Rock, California, Sept. 14, 2023.

Irfan Khan | Los Angeles Times | Getty Images

The Food and Drug Administration on Wednesday approved the latest round of Covid vaccines in the U.S., but set new limits on who can get them.

The agency ended its broader authorization of the shots, only clearing them for people at higher risk of severe illness. That includes those 65 and up and younger adults with at least one underlying condition that puts them at higher risk.

The move could complicate access to the shots for millions of Americans, and raises questions about whether insurance plans will still cover them for healthy adults.

“The emergency use authorizations for Covid vaccines, once used to justify broad mandates on the general public during the Biden administration, are now rescinded,” Health and Human Services Secretary Robert F. Kennedy Jr. said in a post on X.

“The American people demanded science, safety, and common sense,” he said. “This framework delivers all three.”

It follows several efforts by Kennedy, a prominent vaccine skeptic, to change and undermine immunizations in the U.S. The new limited authorizations are a break from U.S. vaccine policy in previous years, which recommended an annual Covid shot for all Americans 6 months and up.

A key panel of vaccine advisors to the Centers for Disease Control and Prevention must vote to recommend the Covid shots. But Kennedy earlier this year gutted that panel and named new members, some of whom are widely known vaccine critics.

In the post, Kennedy said the shots are available for all patients who choose them after consulting with their doctors. But it’s unclear how easily patients without high risk factors will be able to get a Covid vaccine.

Kennedy said the FDA has authorized Moderna‘s shot for those 6 months and up, Pfizer‘s vaccine for people ages five and up and Novavax‘s jab for those ages 12 and up, but for those specifically at higher risk of getting severely sick from the virus.

Adults ages 65 and up are at higher risk of severe Covid, and so are younger adults who are immunocompromised or have underlying medication conditions such as cancer, obesity, diabetes, chronic kidney disease and heart diseases, according to the CDC’s website.

In a release, Pfizer confirmed that the FDA had cleared its updated Covid shot for use in adults 65 and above and those ages five through 64 with at least one underlying condition that puts them at high risk for severe illness. The company will begin shipping the shot immediately, and it will be available in pharmacies, hospitals and clinics nationwide “in the coming days.”

In a separate release, Moderna also confirmed that its updated Covid shot is approved for those 65 and up and people 6 months through 64 years of age who are at higher risk of severe illness. The company added that its new, next-generation Covid vaccine is approved for older adults and high-risk patients ages 12 through 64. Moderna said it expects the shots to be available in the coming days.

Shares of Pfizer and Moderna were trading slightly higher Wednesday afternoon, while Novavax shares dipped.

This is breaking news. Please refresh for updates.



Source

Healthy Returns: 2026 will be the year of obesity pills from Novo Nordisk, Eli Lilly
Health

Healthy Returns: 2026 will be the year of obesity pills from Novo Nordisk, Eli Lilly

Daniel Grill | Tetra Images | Getty Images A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. GLP-1 pills for obesity are closer than ever.  2026 is likely the year that two new oral weight loss […]

Read More
Pfizer’s modest 2026 outlook shows its big investments will take time to pay off
Health

Pfizer’s modest 2026 outlook shows its big investments will take time to pay off

Smith Collection | Archive Photos | Getty Images Pfizer on Tuesday forecast modest 2026 guidance as it looks to longer-term investments in its pipeline to counter waning Covid product sales and declines from older drugs. Those hurdles aren’t surprising or new for Pfizer, which has seen a dramatic decline in Covid vaccine and antiviral sales […]

Read More
Trump says he’s ‘strongly’ considering reclassifying pot via executive order
Health

Trump says he’s ‘strongly’ considering reclassifying pot via executive order

Bill Schmitt Jr. (C) joins cannabis reform protesters outside the White House to call on U.S. President Joe Biden “to take action on cannabis clemency before the November general election” October 24, 2022 in Washington, DC. Win Mcnamee | Getty Images Pot stocks failed to light up for a second day on Monday even after […]

Read More